Plain-English translation of NCT06280092 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Epilepsy research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a small pilot study testing whether adipose-derived mesenchymal stem cells ()—cells derived from fat tissue—can be safely injected directly into the brain during deep brain stimulation surgery for epilepsy. Researchers want to see if this approach is feasible and safe, and whether it shows any positive effects on brain imaging after surgery. Only 5 people will participate in this early-stage trial.
Epilepsy that doesn't respond to anti-seizure medications is a serious condition affecting many people, and surgery options are limited. Researchers are exploring whether stem cells might offer a new way to reduce seizures or improve outcomes when combined with existing surgical treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would undergo the planned deep brain stimulation surgery, and during that same surgery, a single dose of stem cells would be injected directly into your brain tissue. The study team would monitor you for any adverse reactions related to the stem cells and perform follow-up MRI scans to check for any changes on imaging. The main focus is evaluating whether the procedure is safe and feasible, rather than proving that the stem cells immediately improve seizure control.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States